Trident Clinical Research Appoints Ex-Genzyme Corporation (GENZ) Europe Exec as New CMO

Trident Clinical Research Appoints Ex-Genzyme Corporation (GENZ) Europe Exec as New CMO

October, 2010 -- One of Australia's largest CROs, Trident Clinical Research, has moved to strengthen its clinical executive with the appointment of Dr David Fuller as the company's Australian-based chief medical officer.

Dr Fuller's primary responsibility will be to manage the development of Trident's broad suite of clinical trial services across a wide range of therapeutic conditions in both drug and medical device areas. Dr Fuller is dually qualified in medicine and pharmacy and has more than 20 years international experience in clinical development and commercialisation of new medicines. Until April this year, Dr Fuller was Chief Medical Officer of Arana Therapeutics, a publicly listed company with over $300m capitalization. Prior to his three years at Arana, Dr Fuller was Vice-President, Clinical and Site General Manager at Genzyme Europe - in Cambridge, UK - where his responsibilities include clinical development activities across several therapeutic areas and the establishment, leadership and management of the Cambridge research and development centre. Dr Fuller has also had leadership roles at Orphan Medical and CeNeS and was responsible for successful clinical product progression, contributing to partnering activities and the rapid expansion of the team and implementation of appropriate organizational structures.

Trident chief executive, Garth Tierney, said that Dr Fuller is an experienced biotech executive with an outstanding background in clinical development. "David brings a wealth of clinical and commercial experience to Trident and expands Trident's biotechnology expertise. As the company continues to expand operations across Australia, New Zealand, India and eventually into Asia, David will be vital to the growth of our clinical trials in all areas," he said.

 

For further information and interviews please contact Tania Ewing on 0408378422

 

 

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.